We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · March 07, 2017

The Effect of Macitentan on Hemodynamic Parameters and the Association With Disease Progression in Pulmonary Arterial Hypertension

European Heart Journal


Additional Info

European Heart Journal
SERAPHIN Haemodynamic Sub-Study: The Effect of the Dual Endothelin Receptor Antagonist Macitentan on Haemodynamic Parameters and NT-proBNP Levels and Their Association With Disease Progression in Patients With Pulmonary Arterial Hypertension
Eur Heart J 2017 Feb 28;[EPub Ahead of Print], N Galiè, P Jansa, T Pulido, RN Channick, M Delcroix, H-A Ghofrani, F-O Le Brun, S Mehta, L Perchenet, LJ Rubin, BKS Sastry, G Simonneau, OSR Souza, A Torbicki

Further Reading